Ascites predicts degree of treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube, and peritoneal cancers
Gynecologic Oncology(2014)
Abstract
Objectives: Bevacizumab with and following cytotoxic chemotherapy has been associated with improved progression-free survival (PFS) but not overall survival (OS) in the primary treatment of advanced ovarian, fallopian tube, and peritoneal cancers. Factors predictive of long-term efficacy have remained elusive. Because malignant ascites has been associated with expression of vascular endothelial growth factor, we investigated the value of ascites as a predictor of efficacy for bevacizumab.
MoreTranslated text
Key words
bevacizumab,advanced epithelial ovarian,fallopian tube,front-line
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined